📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. (2018)

First Author: McCarthy EM

Attributed to: MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/rheumatology/kex395

PubMed Identifier: 29216396

Publication URI: http://europepmc.org/abstract/MED/29216396

Type: Journal Article/Review

Volume: 57

Parent Publication: Rheumatology (Oxford, England)

Issue: 3

ISSN: 1462-0324